NewAmsterdam Pharma Company N.V.

NasdaqGM:NAMS

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Pharmaceuticals

💉 Vaccines

Location

Netherlands

Market Cap

USD 2.07 B

Share Price

USD 18.40

Avg Daily Volume

921,979

Change (1 day)

1.04%

Change (1 year)

-6.27%

Change (YTD)

-28.41%

NewAmsterdam Pharma Company N.V. Revenue Year-on-Year (YoY) growth for the Trailing 12 Months (TTM) ending March 31, 2025: 631.27%

NewAmsterdam Pharma Company N.V. Revenue Year-on-Year (YoY) growth is 631.27% for the Trailing 12 Months (TTM) ending March 31, 2025. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period. Year-on-Year (YoY) growth is the change in a financial metric compared to the same period in the previous year, expressed as a percentage.

NewAmsterdam Pharma Company N.V. Revenue for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 6.45 M, a -89.55% change year over year.
NewAmsterdam Pharma Company N.V. Revenue for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 61.71 M, a 31.99% change year over year.
NewAmsterdam Pharma Company N.V. Revenue for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 46.75 M.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Revenue Year-on-Year (YoY) growth	Gross Profit	Operating Income	EBIT

NasdaqGM: NAMS

NewAmsterdam Pharma Company N.V.

CEO	Dr. Michael Harvey Davidson FACC, Facp., M.D.
IPO Date	Feb. 9, 2021
Location	Netherlands
Headquarters	Gooimeer 2-35
Employees	68
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Pharmaceuticals 💉 Vaccines

Description

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.